Oncology Research
Researchers from University of California Detail Findings in Oncology Research
Published in Cancer Weekly, November 22nd, 2011
2011 NOV 22 -- "Hypericin is a potent inhibitor of glioma growth in vitro. To examine whether synthetic oral hypericin can be tolerated by patients with recurrent malignant gliomas (anaplastic astrocytoma and glioblastoma) and to investigate its efficacy against these tumors, the authors undertook an open-label, sequential dose escalation/deescalation tolerance study," scientists writing in the journal Cancer report.
"Patients with documented recurrent or progressive malignant gliomas who had received standard radiation therapy with or without chemotherapy were included. Patients were excluded for previous treatment with agents known to contain...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2011-11-22)
More Articles from Cancer Weekly
- Colon Cancer
Almac Publishes Stage II Colon Cancer Recurrence Signature in the Journal of Clinical Oncology - Testicular Cancer
Data from J. Heinzelbecker et al Provide New Insights into Testicular Cancer - Bioscience
Data from National Yang Ming University Provide New Insights into Bioscience - Lung Cancer
Data from Pontifical Catholic University Advance Knowledge in Lung Cancer - Indicators and Reagents
Data from University of Michigan Advance Knowledge in Indicators and Reagents - Colon Cancer
Data on Colon Cancer Published by Researchers at University of North Carolina - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
